<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01323296</url>
  </required_header>
  <id_info>
    <org_study_id>10/S1103/50 (REC REF)</org_study_id>
    <nct_id>NCT01323296</nct_id>
  </id_info>
  <brief_title>Ferumoxytol for Magnetic Resonance Imaging of Myocardial Infarction</brief_title>
  <official_title>Ferumoxytol for Magnetic Resonance Imaging of Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators wish to examine whether a novel 'nanoparticle' of iron oxide, administered
      intravenously allows an area of heart muscle damage after heart attack to be visualised using
      a magnetic resonance scanner.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using ferumoxtran (Feraheme) as a USPIO contrast agent for magnetic resonance imaging at 3
      Tesla, we aim to conduct the first clinical study to examine the utility of this novel
      contrast agent to image myocardial inflammation after myocardial infarction.

      We will test the following hypotheses in patients who have suffered recent acute myocardial
      infarction.

        1. Intravenous injection of ferumoxytol accumulates at the site of myocardial infarction
           and this can be visualised by magnetic resonance imaging.

        2. The spatial extent of the MRI signal change evoked by ferumoxytol in the myocardium is
           proportional to the volume of infarcted myocardium (as assessed by a gadolinium
           late-enhancement study).

        3. Myocardial MRI signal change evoked by ferumoxytol is positively correlated with blood
           markers of systemic inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in myocardial T2* magnetic resonance signal</measure>
    <time_frame>Before, 1 day, 2 days, 4 days, 1 week and 1 month post ferumoxytol</time_frame>
    <description>Change in T2*weighted myocardial signal as assessed by magnetic resonance imaging before and after ferumoxytol administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in systemic blood markers of inflammation</measure>
    <time_frame>Before, 1 day, 2 days, 4 days, 1 week and 1 month after administration of ferumoxytol</time_frame>
    <description>Change in systemic (blood) markers of inflammation over time after myocardial infarction and correlation with T2*weighted MR signal after administration of ferumoxytol.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Ferumoxytol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be administered intravenous ferumoxytol 1 - 3 days following myocardial infarction after baseline cardiac magnetic resonance scanning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects who have suffered myocardial infarction will undergo cardiac magnetic resonance imaging at the same time points as those in the 'ferumoxytol' arm but will not receive ferumoxytol or placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ferumoxytol</intervention_name>
    <description>One dose of intravenous ferumoxytol (4 mgFe/kg body weight at a rate of up to 1 mL/sec)</description>
    <arm_group_label>Ferumoxytol</arm_group_label>
    <other_name>Feraheme; Advanced Magnetics, Inc., Cambridge, MA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presentation with myocardial infarction (either 'ST-elevation' myocardial infarction
             or 'non-ST-elevation' myocardial infarction

          -  Troponin I ≥ 10 IU/mL at 12 hours after the onset of chest pain

          -  Age 18 - 80 years inclusive

        Exclusion Criteria:

          -  Known critical (≥95%) left main stem coronary artery disease

          -  Continued symptoms of angina at rest or minimal exertion

          -  Atrial fibrillation

          -  Symptomatic heart failure; Killip Class ≥2.

          -  Hepatic failure (Childs-Pugh grade B or C) or renal failure (estimated glomerular
             filtration rate &lt;25 mL/min)

          -  Contraindication to magnetic resonance imaging

          -  Past history of systemic iron overload/haemochromatosis

          -  Patients with known allergy to dextran- or iron-containing compounds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David E Newby, FRCP, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Midlothian</state>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Midlothian</state>
        <zip>EH16 4SU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2011</study_first_submitted>
  <study_first_submitted_qc>March 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2011</study_first_posted>
  <last_update_submitted>December 3, 2014</last_update_submitted>
  <last_update_submitted_qc>December 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Magnetic resonance</keyword>
  <keyword>Nanoparticle</keyword>
  <keyword>Iron</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrosoferric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

